Why the study?
Is readministration of abciximab associated with equal efficacy and safety in patients undergoing coronary interventions?
Population
35 patients who received two doses of abciximab at separate intervals at a single-operator community-hospital
Design
Case_series
Authors
Loading...
Abciximab readministration appeared tolerated in this case; leaves open questions on efficacy and safety for coronary interventions.
Is readministration of abciximab associated with equal efficacy and safety in patients undergoing coronary interventions?
Readministration of abciximab appears to be well tolerated without evidence of altered efficacy or safety in a small community hospital cohort.
Arjomand et al. (1999) studied this question.